hyper-CVAD联合帕纳替尼一线治疗费城染色体阳性急性淋巴细胞白血病的长期随访:单中心2期研究
这项单中心、2期、单臂试验纳入76例初治费城染色体阳性急性淋巴细胞白血病成人患者,接受hyper-CVAD与帕纳替尼交替方案治疗。3年无事件生存率为70%(95%CI 56-80)。最常见3-4级不良事件为感染(86%)。作者认为该方案可能成为新的标准治疗,但需随机3期研究验证。
要点
- 76例初治Ph+ ALL患者接受hyper-CVAD联合帕纳替尼治疗,3年无事件生存率70%(95%CI 56-80)。
- 最常见3-4级不良事件为感染(86%)、转氨酶升高(32%)、胆红素升高(17%)。
- 6例患者在治疗期间死亡,其中感染3例(4%)、出血1例(1%)、早期帕纳替尼相关心肌梗死2例(方案修订后未再发生)。
核心结论
- 化疗联合帕纳替尼可使初治费城染色体阳性急性淋巴细胞白血病患者获得长期缓解。
- 该方案可能成为该人群新的标准治疗。
- 需要随机3期研究比较该联合方案与化疗联合早期代酪氨酸激酶抑制剂的疗效。
研究设计与样本
- 单中心、2期、单臂试验,在美国开展,持续入组中。
- 纳入76例既往未治疗的成人费城染色体阳性急性淋巴细胞白血病患者,中位年龄47岁(IQR 39-61)。
- 患者于2011年11月19日至2018年4月4日入组并接受治疗。
- 方案为8个21天周期,hyper-CVAD与大剂量甲氨蝶呤和阿糖胞苷交替。
- 帕纳替尼第1周期前14天口服45 mg/日,后续周期持续45 mg/日;37例治疗后方案修订,第2周期起减至30 mg/日,达完全分子学缓解后进一步减至15 mg/日。
主要发现
- 3年无事件生存率为70%(95%CI 56-80)。
- 最常见3或4级不良事件:感染65例(86%)、转氨酶升高24例(32%)、胆红素升高13例(17%)、胰腺炎13例(17%)、高血压12例(16%)、出血10例(13%)、皮疹9例(12%)。
- 6例患者在研究治疗期间死亡;感染死亡3例(4%),出血死亡1例(1%)。
- 2例患者死于与早期帕纳替尼使用相关的心肌梗死,两例死亡均未发生在方案修订后。
关键数值与推荐
- 完全分子学缓解定义为无可定量BCR-ABL1转录本。
- 主要终点为意向治疗人群的3年无事件生存率。
- 入组标准包括年龄18岁及以上、ECOG体能状态评分2分或以下、左心室射血分数高于50%、血清胆红素≤3.0 mg/dL且血清肌酐≤3.0 mg/dL(除非研究者判断较高水平由白血病所致)。
临床怎么用
- 作者认为化疗联合帕纳替尼可能代表该人群新的标准治疗。
- 作者认为需要随机3期研究评估该联合方案与化疗联合早期代酪氨酸激酶抑制剂的疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of chemotherapy and ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukaemia has the potential to be a new standard of care for the disease; however, long-term efficacy and safety data are needed. Our aim was to evaluate the long-term efficacy and safety of this regimen in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia in this ongoing phase 2 trial. METHODS: In our single-centre, phase 2, single-arm trial in the USA, adult patients with previously untreated Philadelphia chromosome-positive acute lymphoblastic leukaemia were sequentially enrolled. Eligible patients had newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia, were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status of 2 or less, a left ventricular ejection fraction above 50%, and adequate hepatic and renal function (serum bilirubin ≤3·0 mg/dL and serum creatinine ≤3·0 mg/dL, unless higher levels were believed to be due to leukaemia at the discretion of the investigator). Patients received eight cycles of 21 days, alternating between two drug combinations: hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) and high-dose methotrexate and cytarabine. Ponatinib was given orally at 45 mg per day for the first 14 days of cycle 1 then continuously at 45 mg per day for the subsequent cycles. After 37 patients were treated, the protocol was amended to reduce the dose of ponatinib to 30 mg per day at cycle 2, with further reduction to 15 mg once a complete molecular response (defined as absence of quantifiable BCR-ABL1 transcripts) was achieved. Patients in complete remission received maintenance with ponatinib daily (30 mg or 15 mg) indefinitely, and with vincristine (2 mg intravenously on day 1) and prednisone (200 mg orally on days 1-5) monthly for 2 years. The primary endpoint was 3-year event-free survival in the intention-to-treat population. The trial is registered at ClinicalTrials.gov, number NCT01424982, and is ongoing and still enrolling patients. FINDINGS: 76 patients with a median age of 47 years (IQR 39-61) were enrolled and treated between Nov 19, 2011, and April 4, 2018. The 3-year event-free survival was 70% (95% CI 56-80). The most common grade 3 or 4 adverse events were infection (n=65, 86%), increased transaminases (n=24, 32%), increased bilirubin (n=13, 17%), pancreatitis (n=13, 17%), hypertension (n=12, 16%), bleeding (n=10, 13%), and skin rash (n=9, 12%). Six patients died while still on study treatment. Three patients (4%) died from infection and one (1%) from haemorrhage. Two patients died from myocardial infarction related to early ponatinib use; neither death occurred after protocol revision. INTERPRETATION: The combination of chemotherapy with ponatinib is effective in achieving long-term remission in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia. This regimen could represent a new standard of care for this population. A randomised, phase 3 study to evaluate the efficacy of this combination compared with chemotherapy plus earlier-generation tyrosine-kinase inhibitors is warranted. FUNDING: Takeda Oncology.
引用
- Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018. PMID: 30501869. doi:10.1016/S2352-3026(18)30176-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。